Observational studyBMC musculoskeletal disorders2026
Total femoral replacement for severe femoral bone loss in non-oncologic patients: high complication rates but acceptable functional outcomes.
Observational study in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe management of severe femoral bone loss is a growing challenge in prosthetic revision surgery, especially in patients who have undergone multiple previous surgeries. In these complex scenarios, total femoral replacement (TFR) has been used as a rescue technique to preserve the limb, despite its association with a high rate of complications. Evidence on functional outcomes and patient-reported outcome measures (PROMs) from patients with nononcological indications is limited. The objective of this study was to analyze the clinical and functional results of and the complications associated with TFR in a nononcology series and to identify possible prognostic factors. MATERIALS AND
methodsIn this retrospective, observational study, 13 consecutive patients who underwent TFR between 2020 and 2024 and who had a minimum follow-up of 18 months were included. Demographic, clinical and surgical variables; implant survival; and postoperative complications were analyzed. Functional evaluations included assessments of the ability to walk, the visual analog scale for pain and collection of PROMs (12-item short form survey (SF-12), Musculoskeletal Tumor Society (MSTS) scale and Western Ontario and McMaster Universities Arthritis Index (WOMAC) test).
resultsThe mean patient age was 75.3 years. The main indication for TFR was peri-/interprosthetic fracture (69.2%), followed by aseptic loosening (23.1%). The average number of previous surgeries was 4.8. Implant survival at one year was 100%; however, 61.5% of the patients required at least one reintervention, with periprosthetic infection being the most frequent complication (38.5%). A total of 92.3% of the patients maintained the ability to walk with assistance, and while the PROMs reflected moderate pain control and limited function, they were indicative of basic independence.
conclusionsDespite the high rate of complications, in patients with severe femoral bone loss, TFR is a valid option for preserving the limb and allowing a faster transition from assisted ambulation in nononcology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.